Corbus Pharmaceuticals doses first patient in 250-patient registrational TEMPO-1 study of CRB-701 in oropharyngeal cancer

Corbus Pharmaceuticals said the first patient has been dosed in TEMPO-1, a 250-patient registrational study of its Nectin-4 ADC CRB-701 in second-line or later oropharyngeal cancer, with response rate as the primary endpoint.

Detected & updated continuously · Source: Nebula